Rubius_Logo.jpg
Rubius Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 08:00 ET | Rubius Therapeutics
Positive Initial Data from Phase 1/2 Trial of RTX-240 in Advanced Solid Tumors Demonstrated Single-Agent Activity Providing Initial Validation of the RED PLATFORM®;Dose Optimization and Enrollment...
Rubius_Logo.jpg
Rubius Therapeutics to Announce First Quarter 2021 Financial Results
April 26, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
April 12, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
April 09, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Prices Upsized Public Offering of Common Stock
March 16, 2021 21:28 ET | Rubius Therapeutics
CAMBRIDGE Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to...
Rubius_Logo.jpg
Rubius Therapeutics Announces Proposed Public Offering of Common Stock
March 15, 2021 16:32 ET | Rubius Therapeutics
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells...
Rubius_Logo.jpg
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
March 15, 2021 07:39 ET | Rubius Therapeutics
RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events  RTX-240 Promoted Trafficking of NK and T Cells into...
Rubius_Logo.jpg
Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors
March 12, 2021 16:30 ET | Rubius Therapeutics
CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
March 10, 2021 16:30 ET | Rubius Therapeutics
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
February 23, 2021 08:00 ET | Rubius Therapeutics
Reported Initial Key Takeaways in January 2021 Showing RTX-240 Stimulates Innate and Adaptive Immunity; Additional Clinical Results to be Presented in Early 2021 Escalated the Dose in...